mTOR as a therapeutic target in patients with gastric cancer


  • Salah-Eddin Al-Batran,

    Corresponding author
    1. Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt, Germany
    • Institut Für Klinische Forschung, Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany
    Search for more papers by this author
    • Tel.: +49-69-7601-3788, Fax: +49-69-7601-3655

  • Michel Ducreux,

    1. Department of Digestive Oncology, Institut Gustave Roussy, Villejuif, France
    Search for more papers by this author
  • Atsushi Ohtsu

    1. Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Search for more papers by this author


The poor long-term outcomes associated with current chemotherapy treatment of patients with advanced gastric cancer suggest a need for novel targeted agents that may confer a better survival benefit. Evidence of mammalian target of rapamycin (mTOR) activation has been demonstrated in patient-derived gastric cancer cells and tumors. This review explores the relevance of the mTOR pathway to gastric cancer pathogenesis and its potential as a therapeutic target in patients with gastric cancer as well as presenting the first available clinical data on mTOR inhibitors in this disease setting. Preclinical data suggest that suppression of the mTOR pathway inhibited the proliferation of gastric cancer cells and delayed tumor progression in in vitro and animal models. In the clinical setting, the mTOR inhibitor everolimus has been active and well tolerated in phase I/II studies of patients with chemotherapy-refractory metastatic gastric cancer. Based on these promising results, everolimus currently is being investigated as a monotherapy or in combination with chemotherapeutic agents in ongoing phase II/III clinical studies.